Better Metastatic Renal Cell Carcinoma Survival at Higher-Volume Facilities Better Metastatic Renal Cell Carcinoma Survival at Higher-Volume Facilities
Patients with metastatic renal cell carcinoma (mRCC) treated at higher-volume facilities survive longer than those treated at lower-volume facilities, according to a registry-based analysis.Reuters Health Information
AbstractPurposeTo compare the outcomes of percutaneous ablation (PA) versus nephrectomy (NE) for small renal masses (SRMs) in patients with T1 renal cell carcinoma and evaluate the role of pre-procedural biopsy in the treatment of SRM.Materials and MethodsRetrospective cohort analysis of patients subjected to PA or NE for SRM (
Publication date: Available online 14 November 2018Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Maria V. Chatziathanasiadou, Evgenios K. Stylos, Efstathia Giannopoulou, Maria-Helen Spyridaki, Evangellos Briasoulis, Haralabos P. Kalofonos, Tim Crook, Nelofer Syed, Gregory B. Sivolapenko, Andreas G. TzakosAbstractSunitinib is a multi-targeted tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor and is currently being investigated against other forms of malignant tumors. Recently a great interest has been emerged for the appli...
ConclusionThe findings from the study suggested that there were pathological differences in multifocal renal tumors, and that papillary carcinoma may be more common than clear cell carcinoma. The recurrence rate and survival rate of multifocal RCC were similar to monofocal tumors. Tumor recurrence may be related to satellite tumor nodules, which can only be detected once surgery is performed.
Publication date: Available online 12 November 2018Source: European UrologyAuthor(s): Suzanne B. Merrill
In patients with previously untreated advanced renal cell carcinoma (RCC) whose tumors were positive for the PD-L1 checkpoint, a combination of the checkpoint inhibitor avelumab and the tyrosine kinase inhibitor (TKI) axitinib increased the median PFS from 8.4 months to 13.8 months when compared with the TKI sunitinib (HR 0.69; P=0.0001).11/14/2018
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018
CIP2A is a well-known oncoprotein whose expression is elevated in multiple human solid tumor types. However, its role in renal cell carcinoma (RCC) development is poorly understood.11/14/2018
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.11/14/2018
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.11/14/2018
Metastasis is the primary cause of death in renal cell carcinoma (RCC). Loss of cell-to-cell adhesion, including tight junctions (TJs) is the initial step in the process of metastasis. Claudin-7 (CLDN7) is a m...